Mirum Completes Bluejay Acquisition, Expands Rare Liver Disease Pipeline
Mirum Pharmaceuticals, Inc. has completed its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases, marking a significant step…
Read More...
Read More...
